The psychedelic-based therapeutics sector is heating up. And within five years, many analysts covering the industry expect it to be scorching. There are plenty of reasons for that to happen. Foremost is that controlled, non-addictive psychedelic formulations are proving to be an effective alternative to highly addictive opioids. While that alone is an excellent incentive for companies to explore a new frontier in how millions of patients can get treated, there’s more to consider. And it’s all positive.
In fact, studies so far show that psychedelic-based therapeutics are overcoming patient treatment resistance, are attractive for their relatively short duration of use, and appear to lack the severe and unintended consequences of using prescription drugs, whose side effects can often become worse than the condition treated. Those advantages, still just a few, contribute to making strong the case that focused attention be given to the benefits compared to risk of this new class of treatment sooner than later. Actually, that’s happening.
In fact, a newly listed NASDAQ company, Lucy Scientific Discovery, Inc. (NASDAQ: LSDI), is already attracting attention and is well on its way to blazing its trail as a leader in this emerging generation of treatment. The company went public on Thursday and volume indicated there is plenty of excitement around the company’s prospects. And not just investors are paying attention.
Fully-Licensed By Health Canada’s Office of Controlled Substances
Beyond investors and medical sector professionals, LSDI is earning, in a good way, government regulatory attention, proven by LSDI being granted a Controlled Drugs and Substances Dealer’s License under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). That license was provided through Health Canada’s Office of Controlled Substances in August of 2021 and at last check appears to be the only one granted to companies exploring the medicinal side of psychedelic compounds.
If that’s the case, LSDI looks ideally positioned to emerge as a distanced leader in a sector estimated to generate upwards of $100 billion in total addressable revenues by 2030. That bullish estimate includes targeting opportunities related to Alcohol Use Disorder, psychiatric conditions, and potentially other indications where the wellness of the mind can offset physical ailments. Thus, when considering where to place focus, whether as an investor, patient, or sector follower, it may be best to align with a mind science company already researching, developing, and manufacturing psychotropic drugs. Lucy Scientific Discovery checks those boxes.
And they are timely to the opportunity. Remember, while the industry is expected to explode higher toward the $100 billion level in less than seven years, it’s already an estimated $30 billion revenue-generating opportunity from just targeting AUD and psychiatric conditions. So, there’s plenty of incentive for LSDI to expedite research and development to tap into that potential. Considering that the emerging psychotropics industry is paving the way to a brighter mental health and overall wellness future, few expect LSDI to waste time leveraging its strengths.
Leading A Sparse Competitive Landscape
Undoubtedly, as a fully licensed manufacturer of controlled compounds, they have a head-start against a competitive landscape still evaluating conceptual phases. Moreover, they are putting its valuable license to work, leveraging its value to advance the frontiers of mind science and facilitate the development of psychotropic and psychedelic treatment therapies, purposely dedicated to producing a variety of high-quality natural, synthetic, and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market.
Perhaps the better news is that unlike others trying to break into the space, LSDI is more than in it; they are creating partnerships to help drive value from its products and research services to expedite the development of medicines and experimental therapies to treat certain psychiatric health disorders and other medical needs, including addiction disorders. Leaning on its IP portfolio, LSDI is already positioned, perhaps even better than big pharma giants like Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), to accrue customer acquisitions, noting that an increasing number of leading universities, hospitals, and other public, private, and government institutions worldwide appear aligned in the same objective: research the benefits and conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances.
Thus, with a NASDAQ listing providing credibility and assuring transparency, siding with LSDI at this early stage may be wise. Yes, there’s a lot more to learn about this company, and that information will likely come quickly from a management team whose stated objective is to maximize its probability of success while minimizing the time and costs required to achieve its goals. And with very low-float and significant insider holdings, investors are also buying into a company whose decisions should fully align with the broader shareholder base. No matter what stock, company, or sector invested, that’s typically the right place to reside.
Disclaimers: Hawk Point Media Group, Llc. is responsible for the production and distribution of this content. Hawk Point Media Group, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Always assume that insiders, advisors, and non-restricted shareholders are selling shares when there is news about their companies. The information made available by Hawk Point Media Group, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. Hawk Point Media, Llc owns ZERO shares of any company it covers and is therefore not buying, holding, or selling during any coverage period or date. In no event shall Hawk Point Media Group, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media Group, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Hawk Point Media Group, Llc., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. HPM, LLC has not been compensated to provide research or content covering Lucy Scientific Discovery, Inc. but has solicited for business and may be compensated for future coverage. If so, that engagement and pertinent financial disclosures will be included within the disclaimers and disclosures section of each article, video, press release, or blog. Readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website or those located at the conclusion of published content.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company Name: Hawk Point Media
Contact Person: Ken Ellis
Email: info@hawkpointmedia.com
Phone: 3057806988
City: Miami Beach
State: Florida
Country: United States
Website: https://hawkpointmedia.com/